Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | President | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 842,307 |
Reported balance
After 2026-07-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-09 · Sale · Disposed 48,502 · Balance 842,307 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 822,508 |
Reported balance
After 2026-07-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-10 · Sale · Disposed 19,799 · Balance 822,508 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 822,240 |
Reported balance
After 2026-07-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-10 · Sale · Disposed 268 · Balance 822,240 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 378,291 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 378,291 F5: Includes the unvested portion of the Reporting Person's RSU grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Includes the unvested portion of the Reporting Person's RSU grants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 13, 2026 21:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 268 | $29.40 | $7,878.40 |
DisclosureSEC source: 0001422996-26-000006 · wk-form4_1783978603.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 822,240 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 21:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 19,799 | $28.61 | $566,409.79 |
DisclosureSEC source: 0001422996-26-000006 · wk-form4_1783978603.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 822,508 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 48,502 | $30.05 | $1,457,630.61 |
DisclosureSEC source: 0001422996-26-000006 · wk-form4_1783978603.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 842,307 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 6,431 | $29.66 | $190,740.24 |
DisclosureSEC source: 0001610717-26-000294 · form4.xml · nonDerivative · entry 4 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 890,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,697 | $28.06 | $47,619.86 |
DisclosureSEC source: 0001610717-26-000294 · form4.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 897,240 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 14,067 | $27.69 | $389,480.06 |
DisclosureSEC source: 0001610717-26-000294 · form4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 898,937 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 9,236 | $27.03 | $249,661.09 |
DisclosureSEC source: 0001610717-26-000294 · form4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 913,004 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 126,000 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001422996-26-000004 · wk-form4_1769476899.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001422996-26-000004 · wk-form4_1769476899.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,012 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:15 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 100 | $23.20 | $2,320.00 |
DisclosureSEC source: 0001422996-26-000002 · wk-form4_1767820531.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 922,240 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:15 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,053 | $22.34 | $45,864.02 |
DisclosureSEC source: 0001422996-26-000002 · wk-form4_1767820531.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 922,340 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:15 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 29,670 | $21.34 | $633,157.80 |
DisclosureSEC source: 0001422996-26-000002 · wk-form4_1767820531.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 924,393 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 9,983 | $22.16 | $221,218.29 |
DisclosureSEC source: 0001422996-25-000015 · wk-form4_1766097305.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,012 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 11,225 | $21.88 | $245,651.27 |
DisclosureSEC source: 0001422996-25-000015 · wk-form4_1766097305.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,995 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:15 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 82,997 | $24.71 | $2,050,598.58 |
DisclosureSEC source: 0001422996-25-000011 · wk-form4_1764969323.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 954,063 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 5,050 | $19.75 | $99,737.50 |
DisclosureSEC source: 0001422996-25-000009 · wk-form4_1763588347.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,037,060 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 7,836 | $20.71 | $162,307.07 |
DisclosureSEC source: 0001422996-25-000009 · wk-form4_1763588347.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,042,110 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $20.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 37,114 | $20.23 | $750,719.72 |
DisclosureSEC source: 0001422996-25-000009 · wk-form4_1763588347.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,049,946 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $20.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:46 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 4,314 | $20.32 | $87,649.70 |
DisclosureSEC source: 0001422996-25-000007 · wk-form4_1762206359.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,087,060 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $20.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 12:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 800 | $22.04 | $17,635.28 |
DisclosureSEC source: 0001422996-25-000005 · wk-form4_1761828546.xml · nonDerivative · entry 4 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,091,374 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.035 to $22.055, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 12:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 29,365 | $21.53 | $632,166.78 |
DisclosureSEC source: 0001422996-25-000005 · wk-form4_1761828546.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,092,174 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 to $22.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 12:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 47,675 | $20.49 | $976,832.15 |
DisclosureSEC source: 0001422996-25-000005 · wk-form4_1761828546.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,121,539 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 12:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 19,019 | $20.19 | $383,944.16 |
DisclosureSEC source: 0001422996-25-000005 · wk-form4_1761828546.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,169,214 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:29 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000014 · wk-form4_1738013385.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:29 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000014 · wk-form4_1738013385.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,220 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 15, 2024 Filed Dec 18, 2024 01:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 17,286 | $16.08 | $277,958.88 |
DisclosureSEC source: 0001724521-24-000178 · wk-form4_1734485750.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,220 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 6,969 | $16.97 | $118,263.93 |
DisclosureSEC source: 0001724521-24-000128 · wk-form4_1718744048.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,506 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 00:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 23,132 | $20.10 | $464,953.20 |
DisclosureSEC source: 0001724521-24-000062 · wk-form4_1709168132.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,188,233 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2023. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 3,900 | $20.06 | $78,234.00 |
DisclosureSEC source: 0001724521-24-000062 · wk-form4_1709168132.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,211,365 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 162,400 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000029 · wk-form4_1706229591.xml · derivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,400 Underlying: Common Stock · 162,400 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000029 · wk-form4_1706229591.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,475 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 6,975 | $20.09 | $140,127.75 |
DisclosureSEC source: 0001724521-24-000008 · wk-form4_1704406959.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,215,265 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the ranges set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 6,259 | $18.09 | $113,225.31 |
DisclosureSEC source: 0001724521-23-000065 · wk-form4_1703106566.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,475 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 6,128 | $17.74 | $108,710.72 |
DisclosureSEC source: 0001724521-23-000065 · wk-form4_1703106566.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,734 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 17, 2023 00:14 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 4,820 | $19.35 | $93,267.00 |
DisclosureSEC source: 0001209191-23-038154 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,862 F2 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:14 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038154 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,682 F1 · kind: Represents a gift to a family trust over which the reporting person has neither voting nor investment control. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 185,900 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-004872 · doc4.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,900 Underlying: Common Stock · 185,900 shares Expires 2033-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004872 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,682 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 701 | $31.23 | $21,892.23 |
DisclosureSEC source: 0001209191-22-061759 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,258 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 3,735 | $30.66 | $114,515.10 |
DisclosureSEC source: 0001209191-22-061759 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,959 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:18 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,789 | $22.29 | $39,876.81 |
DisclosureSEC source: 0001209191-22-038386 · doc4.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,037 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:18 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 748 | $21.71 | $16,239.08 |
DisclosureSEC source: 0001209191-22-038386 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,826 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.14 to $22.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:18 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,333 | $20.72 | $48,339.76 |
DisclosureSEC source: 0001209191-22-038386 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,574 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-22-017973 · doc4.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-03-07 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017973 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,407 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:02 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014850 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,222,240 F1 · price: Gift to a family trust over which the reporting person has neither voting nor investment control. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 401 | $41.42 | $16,610.94 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 6 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,157 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 304 | $40.57 | $12,334.25 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 5 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,558 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 157 | $39.67 | $6,228.49 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 4 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,862 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 246 | $38.79 | $9,541.77 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,019 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.